Advanced searches left 3/3

Peripheral Neuropathy - Crossref

Summarized by Plex Scholar
Last Updated: 15 July 2022

* If you want to update the article please login/register

Leveraging GWAS Data Derived From a Large Cooperative Group Trial to Identify a SNP Cluster Associated With the Risk of Taxane-induced Peripheral Neuropathy

Methods We reviewed GWAS results obtained from ECOG-5103, first identifying SNPs that were most closely associated with CIPN risk using Fisher's ratios to determine taxane-associated CIPN risk using the Fisheru2019s ratio.

Source link: https://doi.org/10.21203/rs.3.rs-219649/v1


Сomprehensive assessment of macro- and microcirculation parameters in patients with type 2 diabetes mellitus and subclinical stage of diabetic peripheral neuropathy during treatment with antihypoxic drug

Partially impaired cardiovascular dysfunction in diabetes mellitus is partial damage to the vascular wall and hemorheological changes in the lumen of blood vessels against the backdrop of persistent hyperglycemia. In patients with T2DM and DPN1, investigate the effects of a drug with antihypoxic effects on the macro- and microcirculation of the capillary bed, arterial stiffness, and endothelial function. In patients with T2DM and DPN1, treatment with Actoveginu00ae does not have an effect on the central hemodynamics and arterial stiffness parameters. The results of the research show that the use of a drug with an antihypoxic effect in T2DM and DPN1 patients greatly raises the parameters of microcirculation, and can therefore be used as pathogenetic therapy at the early stages of diabetes development.

Source link: https://doi.org/10.30629/2658-7947-2022-27-3-35-46


Remote Research: Resources, Intervention Needs, and Methods in People with Diabetes and Peripheral Neuropathy

Background: The SARS-CoV-2 pandemic orders were particularly important for older adults with type 2 diabetes who were at risk of severe COVID-19 complications. The purpose of this study was to determine resource needs, future telehealth issues, and the ability to incorporate common research and clinical standards of glycemic control, physical fitness, endurance monitoring, and quality of life outcomes to a telehealth setting. Methods: Twenty-one participants with type 2 diabetes and peripheral neuropathy were recruited from a longitudinal study. The evaluation of technology needs and future telehealth needs was determined. Twelve participants used computers; nine used phones for study completion; nine used phones for research completion. Twenty people expressed interest in participating in future telehealth studies relating to balance, fitness, and diabetes control. Conclusions: To conclude a long-term telehealth intervention, seniors with type 2 diabetes and peripheral neuropathy will need medical and personal assistance. www. clinicaltrials. gov/ aa01-0101 is registered at https://clinicaltrials. gov/.

Source link: https://doi.org/10.1177/19322968221103610


Correlation between Interleukin 10 Serum Levels and Severity of Peripheral Neuropathy in Multibacillary Leprosy Patients a Research Article

When the nerve injury is greater than 30% of peripheral nerve fibers, clinical reports of leprosy neuropathy are obtained. Purpose of the Study The aim of the study is to determine if interleukin levels 10 serum and peripheral neuropathy. Methods of the Study The research was conducted by the researcher's methods include cross-sectional analysis of 30 individuals with multibacillary leprosy aged 18-65 at Kelet Hospital Jepara from September to October 2021. The Interleukin level 10 serum test can be determined by testing blood samples. The majority of patients with multibacillary leprosy are men, according to a research study. Keywords: multibacillary leprosy, interleukin 10, peripheral neuropathy, and epidermal neuropathy in multibacillary leprosy Keywords: multibacillary leprosy, interleukin ten levels and the severity of peripheral neuropathy in multibacillary leprosy have been found, as well as a strong and significant correlation between serum interleukin ten levels and peripheral neuropathy with rho in multibacillary leprosy.

Source link: https://doi.org/10.14710/dmj.v11i2.32648


Ayurvedic review on diabetic peripheral neuropathy

Diabetic peripheral neuropathy is one of the oldest disorders with the highest incidence of 40-50% and is on the rise of hospital stay among diabetic mallitus patients and the leading cause of foot ulcers, with complications including leg amputation and cost associated with it. Diabetes mellitus, as well as Diabetes mellitus, can be diagnosed and tracked as the same disease. Foot ulcers can be greatly reduced if foot ulcers and its consequences by using the ayurveda principles in diagnosis and treatment of diabetes mellitus and its complications, such as DPN.

Source link: https://doi.org/10.51648/jac.36


miRNA-155 silencing reduces sciatic nerve injury in diabetic peripheral neuropathy

Neuropathic pain is one of the most common problems associated with diabetes mellitus that affects quality of life. Hence, the new analysis sought to determine the role of miR-155 in diabetic peripheral neuropathy. In vitro DPN models were created using rabbit Schwann cells after receiving 5. 5 mM glucose in a study. In vivo, miR-155 antagomir or agomir was employed to investigate the effects of miR-155 on motor and sciatic nerve conduction velocity, angiogenesis, and immune response in vivo. Also, miR-155's effects were reversed after Nrf2 was restored both in vitro and in vivo, according to another. In DPN, miR-155 was detected and stifled Nrf2 was shown. Taken together, the key findings of our analysis reveal that miR-155 targeted and suppressed Nrf2 suppression. MiR-155 silencing was found to reduce sciatic nerve injury in DPN, DPN's sciatic nerve injury, raising the possibility of a therapeutic target for DPNs.

Source link: https://doi.org/10.1530/jme-19-0067


Endothelin-1 predicts incident diabetic peripheral neuropathy in Type 2 Diabetes: a cohort study

Introduction Diabetic peripheral neuropathy is a common microvascular complication among patients with type 2 diabetes. We investigated whether baseline plasma endothelin-1 and other cardiovascular and vascular risk factors predicted the occurrence of DPN. On either foot of a three-year follow-up, but not at baseline, Incident DPN was considered present if unusual finding in monofilament or neurothermometer testing was u226525 volts, but not normal at baseline. Results At baseline, mean age of patients was 57. 4 years old and the prevalence of DPN was 10. 8%, according to the study. 1250 patients were returned for follow-up examination after a 10. 7% incidence of DPN out of the 1767 patients without DPN. After adjustment for glycemic control, eGFR, albuminuria, peripheral arterial disease, and retinopathy status, patients with incident DPN had significantly higher baseline endothelin-1, systolic blood pressure, and diabetes duration, according to incident DPN.

Source link: https://doi.org/10.1530/eje-19-0523


Association between serum cystatin C and diabetic peripheral neuropathy: a cross-sectional study of a Chinese type 2 diabetic population

Objective Serum cystatin C is a sensitive marker of kidney function, and new studies have revealed that CysC plays a key role in degenerative disorders in both the central and peripheral nervous systems. The aim of this research was to investigate the correlation between serum CysC and diabetic peripheral neuropathy in patients with type 2 diabetes. Conclusions Serum CysC levels were significantly higher in DPN patients than in patients with warnings of DPN and non-DPN patients. In quartile 2, quartile 3, and quartile 4, the risk of DPN was much higher in quartile 2, quartile 3, and quartile 4, relative to quartile 1. Conclusions: High serum CysC level is closely related to DPN and may be a potential biomarker for DPN in type 2 diabetic patients.

Source link: https://doi.org/10.1530/eje-14-0381


THERAPY OF ENDOCRINE DISEASE: A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy

Objectives: To determine the effects and safety of 300 mg b1-lipoic acid given i. v. , we need to investigate the effect and safety of the 300 mg of u2013600 mg u03b1-lipoic acid. Methods We looked into Medline, Embase, and Cochrane's central registry of Controlled Trials and Chinese biological medicine for clinical trials of ALA in the treatment of DPN. The key findings were efficacy, median motor nerve conduction rate, median sensory nerve conduction velocity, peroneal MNCV, and Peroneal SNCV. Results Fifteen random controlled trials met the inclusion criteria. Nerve conduction velocities in the treatment group increased in contrast to the control group. Mean differences in nerve conduction velocities were 4. 63 for median MNCV, 3. 17 for peroneal MNCV, 4. 25 for median SNCV, 4. 25 for peroneal MNCV, and 3. 65 for peroneal SNCV in favor of the treatment group, with 3. 67 for peroneal SNCV, 4. 25 for median MNCV, 4. 25 for peroneal MNCV, and 3. 65 for peroneal SNCV, and 3. 65 for peroneal SNCV veloca velocities reported velocities velocities, 4. 17 for median MNCV, 4. 25 for peroneal MNCV, 4. 25 for peroneal MNCV, 3. 17 for peroneal SNCV, and SNCV, 3. 67 for peroneal SNCV, and 3. 17 for peroneal SNCV, 3. 17 for peroneal MNCV, and 3. 65 for peroneal SNCV, 3. 67 for peroneal MNCV, 3. 65 for peroneal MNCV, and SNCV, and 3. 65 Conclusions This meta-analysis has shown that ALA therapy is safe and that the therapy can significantly improve both nerve conduction velocity and positive neuropathic signs.

Source link: https://doi.org/10.1530/eje-12-0555


Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy induced peripheral neuropathy

In 14,900 European-ancestry patients receiving chemotherapeutic agents in 14 randomized controlled trials, we conducted a meta-analysis of time-to-PN using WGS data. Intron 13 of GRID2 and rs115575220 downstream of SCG2, we found two low frequency variants of PN risk, rs17020773 in intron 13 of GRID2 and rs116575220 downstream of SCG2. We also found two low frequency variants of PN risk: rs17020773 in intron 13 of GRID2 and rs115575220 downstream of SCG2. According to an analysis of snRNA-seq from human dorsal root ganglia, the expression of GPR68 was the highest among mechano-thermo sensitive nociceptors. Inhibition of GPR68 signaling may be a way to avoid PN in cancer patients.

Source link: https://doi.org/10.21203/rs.3.rs-1816977/v1

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions